Lista de obras - Giulia Siravegna - Dominio Público Uruguay

Abstract LB-75: Blood-based molecular detection of acquired resistance to anti-EGFR therapies in colorectal cancer patients

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

artículo científico publicado en 2016

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

artículo científico publicado en 2015

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

artículo científico publicado en 2013

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

artículo científico publicado en 2014

Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients

artículo científico publicado en 2015

Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment

scientific article published on 17 September 2020

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

artículo científico publicado en 2015

Detection of circulating tumor DNA in early- and late-stage human malignancies

artículo científico publicado en 2014

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

artículo científico publicado en 2015

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

artículo científico publicado en 2016

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

artículo científico publicado en 2012

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

artículo científico publicado en 2017

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

artículo científico publicado en 2015

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

scientific article published on 01 July 2015

Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.

artículo científico publicado en 2017

Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance

artículo científico

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.

artículo científico

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

artículo científico publicado en 2017

Integrating liquid biopsies into the management of cancer

artículo científico publicado en 2017

Liquid biopsies to evaluate early therapeutic response in colorectal cancer: Figure 1

article

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

artículo científico publicado en 2016

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

artículo científico publicado en 2016

Minimal residual disease in breast cancer: in blood veritas

artículo científico publicado en 2014

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer

artículo científico publicado en 2015

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

artículo científico publicado en 2016

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

artículo científico

Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer

artículo científico publicado en 2017

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma

artículo científico publicado en 2016

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

artículo científico publicado en 2016

Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.

artículo científico publicado en 2017

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

artículo científico publicado en 2015

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

artículo científico publicado en 2016

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients

artículo científico publicado en 2019

Lista de obras de Giulia Siravegna

Abstract LB-75: Blood-based molecular detection of acquired resistance to anti-EGFR therapies in colorectal cancer patients

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients

Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Detection of circulating tumor DNA in early- and late-stage human malignancies

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.

Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Integrating liquid biopsies into the management of cancer

Liquid biopsies to evaluate early therapeutic response in colorectal cancer: Figure 1

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

Minimal residual disease in breast cancer: in blood veritas

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients